On August 11, 2023, Antengene Corporation Limited (“Antengene”) and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”) jointly announced an agreement to collaborate on the commercialization of XPOVIO® and other products containing or composed of selinexor in mainland China.
Under the terms of the agreement, Antengene will continue to be responsible for the research and development, regulatory approvals, product supply and distribution of XPOVIO®, and Hansoh Pharma will be exclusively responsible for the commercialization of XPOVIO® and other products containing or composed of selinexor in mainland China. Antengene will receive an upfront payment of up to RMB 200 million and may receive milestone payments of up to RMB 535 million from Hansoh Pharma. Antengene will continue to record revenue from sales of XPOVIO® in mainland China and Hansoh Pharma will receive a service fee from Antengene.
JunHe’s team was engaged by Antengene to review and revise the transaction documents and was highly recognized by the client for their professional, efficient and detail-oriented legal services during the deal.